Shopping Cart
- Remove All
- Your shopping cart is currently empty
NLRP3-IN-45 (D6) serves as an inhibitor specifically targeting the NLRP3 inflammasome, demonstrated through its ability to curb the activity of IL-1β (IC 50 = 41.79 nM). It effectively prevents the activation of the NLRP3 inflammasome while sparing the initial stages of its activation process. Furthermore, NLRP3-IN-45 has been shown to selectively inhibit NLRP3 inflammasome activation in the LPS-induced acute lung injury (ALI) mouse model.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
10 mg | Inquiry | Backorder | |
50 mg | Inquiry | Backorder |
Description | NLRP3-IN-45 (D6) serves as an inhibitor specifically targeting the NLRP3 inflammasome, demonstrated through its ability to curb the activity of IL-1β (IC 50 = 41.79 nM). It effectively prevents the activation of the NLRP3 inflammasome while sparing the initial stages of its activation process. Furthermore, NLRP3-IN-45 has been shown to selectively inhibit NLRP3 inflammasome activation in the LPS-induced acute lung injury (ALI) mouse model. |
In vitro | NLRP3-IN-45 (0.2-5 μM, 1 h) inhibits the activation of NLRP3 inflammasomes in BMDMs cells without affecting the activation of AIM2 and NLRC4 inflammasomes. Additionally, NLRP3-IN-45 does not interfere with the priming stage of NLRP3 inflammasome activation. |
In vivo | Administered once daily at doses ranging from 0.1 to 10 mg/kg for three days, NLRP3-IN-45 significantly inhibits the activation of the NLRP3 inflammasome in a mouse model of acute lung injury, thereby offering a protective effect against the condition. |
Molecular Weight | 483.53 |
Formula | C27H30FNO6 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.